Parsaclisib Improved Myelofibrosis Symptoms in Patients With Suboptimal Response to Ruxolitinib
At 12 weeks, most patients had a reduction in spleen volume.
Myelofibrosis
LCL161 Shows Moderately Positive Objective Response Rate in Patients With Myelofibrosis
Researchers sought to determine whether LCL161 would induce a response in patients with myelofibrosis.
Depression Common Among Patients With a Myeloproliferative Neoplasm
Using validated tools, investigators determined that patients with a MPN were likely to experience significant symptoms of depression.
Cutaneous AEs Are Common in Patients With MPNs Treated With Hydroxyurea
Previously conducted retrospective studies may have underestimated the incidence of hydroxyurea-related skin toxicity in patients with MPNs.
Characteristics of Ruxolitinib Discontinuation Syndrome in Myelofibrosis
Ruxolitinib discontinuation syndrome was associated with spleen length and platelet count, although severe cases were rare in a cohort of patients with myelofibrosis.
Study Results Find Interaction Between Fedratinib and a Strong Inhibitor of CYP3A4
Fedratinib, a selective inhibitor of JAK2, was approved in 2019 by the US FDA for the treatment of certain groups of patients with myelofibrosis.
Management of Patients With Myelofibrosis Experiencing Ruxolitinib Failure
Identification of the underlying pattern for ruxolitinib failure in patients with myelofibrosis is a significant factor in determining appropriate treatment.
Second Cancers Pose Significant Mortality Risk in Myeloproliferative Neoplasms
Researchers sought to determine whether second cancers associated with MPNs affect a patient’s prognosis, and whether cytoreductive or antiplatelet therapies affect outcomes.
Ruxolitinib May Be Effective for Reducing Spleen Length in Patients With Myelofibrosis
By week 24 of the study, a reduction in palpable spleen length of at least 50% was reported in more than half of patients who underwent splenomegaly.
Why Do Patients With Myelofibrosis Discontinue Ruxolitinib?
Researchers assessed how the reasons that led to discontinuation of ruxolitinib influenced survival in patients with myelofibrosis.
- Loading...
Loading...
Next post in General Hematology
Loading... 
Loading...